Nevertheless, TNF-α  blocking agents such as infliximab have been used in the treatment of refractory cases of GPA [41] and it has been shown that pretreatment of cells with TNF-α  induces PR3 membrane expression and secretion [31]. This evidence concerns the gene PRTN3 and granulomatosis with polyangiitis.